Kurniawan A., Cano LH., Mayenco ND., Unnikrishnan S., Elsinga PH., Antunes IF., de Vries EFJ., Cornelissen B.

In recent years, numerous studies have investigated the use of poly (ADP-ribose) polymerase (PARP) inhibitors, labelled with various radionuclides, as agents for targeted radionuclide therapy. This review discusses current advances in studies with radiolabelled PARP inhibitors for targeted radionuclide therapy, focusing on radionuclide selection and (radio)biological properties. We highlight differences between radionuclides and their efficacy in killing cancer cells, while safeguarding healthy tissue. Furthermore, important biomarkers and dosimetry are explored, providing insights and future directions for advancing radiolabelled PARP inhibitors.

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.

Kurniawan A., Cano LH., Mayenco ND., Unnikrishnan S., Elsinga PH., Antunes IF., de Vries EFJ., Cornelissen B.

DOI

Type

Publication Date

Keywords